The European CDMO Model, Powering Biologics Innovation

As biologic modalities grow more complex, and development timelines accelerate, the ability to transform innovation into robust, scalable, and compliant manufacturing has become a critical determinant of success.

Europe is at the heart of advanced biologics development
In this dynamic environment, CDMOs are evolving rapidly. They are increasingly expected to support drug development from the earlies stages, seamlessly integrating process development, analytics, quality and large-scale manufacturing considerations from the outset.
3PBIOVIAN was built around this integrated approach. As a pan European CDMO, the company supports biologics and advanced therapy programs from early development through clinical supply and commercial manufacturing, acting as a long-term partner rather than a transactional service provider.

Early decisions that have a lasting impact
For biotech and pharmaceutical companies across Europe, the objective is clear: to transform promising science into reliable products that can efficiently progress through clinical development into commercial supply. In this process, early decisions around a drug candidate’s manufacturability, scalability, and regulatory alignment often determine the long-term viability of the program.

Technological breadth and industrial integration
3PBIOVIAN’s capabilities span a wide range of expression systems and modalities, including microbial and mammalian platforms for recombinant proteins, as well as viral vectors, plasmid DNA and advanced therapy products. This technological breadth allows development programs to evolve with flexibility, selecting the most appropriate manufacturing route as scientific and clinical needs change.

With GMP manufacturing sites in Spain (Pamplona) and Finland (Turku), ­3PBIOVIAN combines industrial-scale capabilities with the agility demanded by Europe’s innovation driven biotech ecosystem. Its services cover both Drug Substance and Drug Product and are designed as a seamless pathway rather than a sequence of disconnected steps.

Quality, People and Execution
A strong quality culture forms the foundation of 3PBIOVIAN’s organization, and is reinforced by multidisciplinary teams with extensive experience across development and manufacturing. In an industry where precision in execution is as vital as innovation, the expertise of people, the strength of collaboration, and the consistency of processes are what truly set organizations apart.

Supporting Europe’s next generation of therapies
As biologics pipelines grow increasingly complex, European CDMOs are assuming a more strategic role in shaping development outcomes. Combining extensive experience and track record with technological breadth, regulatory expertise, and an integrated end to end offering, 3PBIOVIAN exemplifies how modern European CDMOs are helping transform promising concepts into therapies that ultimately reach patients.

Contact us:
3PBIOVIAN
www.3pbiovian.com

This article was originally published in CDMO-Special of European Biotechnology Magazine Spring 2026.